Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $188

Benzinga · 3d ago
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $183 to $188.